Literature DB >> 11058619

Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.

Q Wei1, L Cheng, C I Amos, L E Wang, Z Guo, W K Hong, M R Spitz.   

Abstract

BACKGROUND: Only a fraction of cigarette smokers develop lung cancer, suggesting that people differ in their susceptibility to this disease. We investigated whether differences in DNA repair capacity (DRC) for repairing tobacco carcinogen-induced DNA damage are associated with differential susceptibility to lung cancer.
METHODS: From August 1, 1995, through April 30, 1999, we conducted a hospital-based, case-control study of 316 newly diagnosed lung cancer patients and 316 cancer-free control subjects matched on age, sex, and smoking status. DRC was measured in cultured lymphocytes with the use of the host-cell reactivation assay with a reporter gene damaged by a known activated tobacco carcinogen, benzo[a]pyrene diol epoxide. Statistical tests were two-sided.
RESULTS: Overall, lower DRC was observed in case patients than in control subjects (P:<.001) and was associated with a greater than twofold increased risk of lung cancer. Compared with the highest DRC quartile in the control subjects and after adjustment for age, sex, pack-years of smoking, family history of cancer, and other covariates, reduced DRC was associated with increased risk of lung cancer in a dose-dependent fashion (odds ratio [OR] = 1.8 with 95% confidence interval [CI] = 1.1-3.1, OR = 2.0 with 95% CI = 1.2-3.4, and OR = 4. 3 with 95% CI = 2.6-7.2 for the second, third, and fourth quartiles, respectively; P:(trend)<.001). Case patients who were younger at diagnosis (<60 years old), female, or lighter smokers or who reported a family history of cancer exhibited the lowest DRC and the highest lung cancer risk among their subgroups, suggesting that these subgroups may be especially susceptible to lung cancer.
CONCLUSION: The results provide evidence that low DRC is associated with increased risk of lung cancer. The findings from this hospital-based, case-control study should be validated in prospective studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11058619     DOI: 10.1093/jnci/92.21.1764

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  118 in total

1.  Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Authors:  Alice J Sigurdson; Irene M Jones; Qingyi Wei; Xifeng Wu; Margaret R Spitz; Douglas A Stram; Myron D Gross; Wen-Yi Huang; Li-E Wang; Jian Gu; Cynthia B Thomas; Douglas J Reding; Richard B Hayes; Neil E Caporaso
Journal:  Carcinogenesis       Date:  2010-10-07       Impact factor: 4.944

2.  CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.

Authors:  Ming Yin; Jingrong Yan; Sheng Wei; Qingyi Wei
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

3.  Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans.

Authors:  Yun-Ling Zheng; Christopher A Loffredo; Anthony J Alberg; Zhipeng Yu; Raymond T Jones; Donna Perlmutter; Lindsey Enewold; Mark J Krasna; Rex Yung; Peter G Shields; Curtis C Harris
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

4.  DNA damage phenotype and prostate cancer risk.

Authors:  O Kosti; L Goldman; D T Saha; R A Orden; A J Pollock; H L Madej; A W Hsing; L W Chu; J H Lynch; R Goldman
Journal:  Mutat Res       Date:  2010-11-21       Impact factor: 2.433

5.  In vitro expression levels of cell-cycle checkpoint proteins are associated with cellular DNA repair capacity in peripheral blood lymphocytes: a multivariate analysis.

Authors:  You-Hong Fan; Zhibin Hu; Chunying Li; Li-E Wang; Zhaozheng Guo; Yawei Qiao; Li Zhang; Wei Zhang; Li Mao; Qingyi Wei
Journal:  J Proteome Res       Date:  2007-03-16       Impact factor: 4.466

6.  Role of inflammation gene polymorphisms on pain severity in lung cancer patients.

Authors:  Cielito C Reyes-Gibby; Margaret R Spitz; Sriram Yennurajalingam; Michael Swartz; Jian Gu; Xifeng Wu; Eduardo Bruera; Sanjay Shete
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-22       Impact factor: 4.254

7.  The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care.

Authors:  Cielito C Reyes-Gibby; Badi El Osta; Margaret R Spitz; Henrique Parsons; Razelle Kurzrock; Xifeng Wu; Sanjay Shete; Eduardo Bruera
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 8.  Markers of oxidant stress that are clinically relevant in aging and age-related disease.

Authors:  Kimberly D Jacob; Nicole Noren Hooten; Andrzej R Trzeciak; Michele K Evans
Journal:  Mech Ageing Dev       Date:  2013-02-18       Impact factor: 5.432

9.  Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Wu Wei; Xiao-Feng He; Jiang-Bo Qin; Jiao Su; Shao-Xia Li; Yi Liu; Ying Zhang; Wei Wang
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

10.  A modified alkaline comet assay for measuring DNA repair capacity in human populations.

Authors:  Andrzej R Trzeciak; Janice Barnes; Michele K Evans
Journal:  Radiat Res       Date:  2008-01       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.